surmount-1 tirzepatide weight loss non-diabetic Relationship of early rapid to efficacy and safety of and semaglutide for obesity: SURMOUNT-5 post hoc analysis SURMOUNT-1 Trial - Cardionerds Twitter

Endocrinologists and psychiatrists should both pay attention to patients emotional status before and after semaglutide use

Wegovy (semaglutide) is a GLP-1 receptor agonist that works by reducing appetite and slowing gastric emptying to facilitate weight loss

A person in a k-hole has likely ingested a very high dose for their body and will experience reduced motor function and dissociation

The new trial tells us that the mechanism of heart benefit is not only dependent on weight loss since a similar magnitude of symptomatic relief was seen in the 2 trials

people describe it as the difference between a smoke alarm that keeps chirping and one that only sounds when there is real smoke